Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.32 |
| ▸ | CLK1 | P49759 | 5/20 | 0.32 |
| ▸ | VNN1 | O95497 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14236264 | 0.90 | VNN1 (0.42) | NTRK1VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL14236233 | 0.90 | NTRK1 (0.41) | NTRK1DYRK1ACLK1CCNT1 | |
| SCHEMBL14235722 | 0.86 | HDAC3 (0.47) | NTRK1DYRK1AHDAC3HDAC1HDAC2 | |
| SCHEMBL14236271 | 0.86 | VNN1 (0.41) | NTRK1VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL14236211 | 0.86 | HDAC1 (0.38) | CYP2C9VNN1CCNT1HDAC3HDAC1 | |
| SCHEMBL14235595 | 0.85 | CYP2C9 (0.36) | NTRK1CYP2C9CYP3A4VNN1CCNT1 | |
| SCHEMBL14236090 | 0.84 | HDAC3 (0.45) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14236274 | 0.83 | VNN1 (0.41) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14235873 | 0.81 | HDAC3 (0.37) | NTRK1CYP2C9CYP3A4VNN1HDAC3 | |
| SCHEMBL12304080 | 0.81 | VNN1 (0.41) | NTRK1CYP2C9VNN1CCNT1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | NTRK1 472/4885CYP2C9 4122/4885CYP3A4 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.